ReproNovo
Switzerland - LausanneBiotechnology
Focus: ReproNovo is a Swiss biotech focused on reproduction assistance treatments, currently advancing a Phase 2 program in semen quality. Founded in 2021, the company is at Series A stage with a highly focused pipeline.
Profile data last refreshed Yesterday · AI intelligence enriched 1w ago
Funding Stage
SERIES A
Open Jobs
0
About ReproNovo
AI assessmentNot HiringNo open roles listed right now. Follow ReproNovo to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
1 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Leflutrozole, Dose 1
Semen QualityClinical Trials (1)
NCT06993155A Clinical Trial Evaluating the Efficacy and Safety of Leflutrozole on Testicular Function
Phase 2Help build intelligence for ReproNovo
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.